Search
Login

If you are a member of the general public and not a healthcare professional, NOVELTY study investigator or AstraZeneca Medical employee, please CLICK HERE to see information tailored to you.

News & events

Home > News & events

Here you can find news and features relating to the NOVELTY study as we embark on this journey of discovery.

Extra news for investigators and AstraZeneca Medical employees

Events

Read More

News

17th November, 2020

Observational studies review published

Read More

14th July, 2020

NOVELTY at ATS 2020

Read More

3rd June, 2020

The COVID-19 pandemic and NOVELTY

Read More

18th March, 2020

An update on NOVELTY governance: the NOVELTY Scientific Community

The NOVELTY Scientific Community was established at the annual face-to-face meeting on 22 January 2020. This new structure represents an evolution in the NOVELTY scientific strategy, setting and delivery, bringing together the separate bodies of the Scientific Committee, the National Principal Investigators and the AstraZeneca science and evidence leads. This new Scientific Community is led by Co-Chairs selected from academia and AstraZeneca. This includes two external experts, Prof. Helen Reddel and Prof. Alberto Papi, joined by AstraZeneca Co-Chair, Dr. Hana Müllerová. The Scientific Community Co-Chairs foster communication among WorkStream leads and prioritise science during regular meetings with them. Together, the...
Read More

10th December, 2019

Severe obstructive lung disease review article published

We are pleased to announce that a review article entitled ‘Defining severe obstructive lung disease in the biologic era: an endotype-based approach’ has been published in the European Respiratory Journal.1 This article, authored by members of the NOVELTY Scientific Committee, reviews the evolving clinical definitions of severe asthma, severe COPD and “asthma–COPD overlap” (i.e. patients with features of both diseases). The findings of this review support the rationale for initiating the NOVELTY study, by highlighting that existing clinical definitions of asthma and COPD do not reflect the known heterogeneity within these diagnoses, nor the potential for overlap between them. The...
Read More

7th April, 2016

A message from the NOVELTY Scientific Committee

We are very pleased to announce the launch of the NOVELTY study, and are enthusiastic to be working with physicians and study centres around the world to increase our knowledge of obstructive lung disease on a global, local and individual patient level.
Read More
19 PARTICIPATING COUNTRIESa
~12,000 ENROLLED PATIENTSa
80% OF PATIENTS HAVE SPIROMETRY DATAb

You are now leaving: http://aznoveltyproject.com/

By following this link you will be leaving the NOVELTY study website.

Please note that AstraZeneca does not take responsibility for the content displayed on other websites.

Continue Return to NOVELTY study